Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.40 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.40 |
| ▸ | STS | P08842 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17630680 | 1.00 | HPGD (0.47) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| SCHEMBL17630844 | 1.00 | HPGD (0.47) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| SCHEMBL31080158 | 0.86 | EPHX1 (0.47) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| SCHEMBL25901853 | 0.86 | EPHX1 (0.47) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| SCHEMBL15740632 | 0.86 | EPHX1 (0.47) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| SCHEMBL25901936 | 0.86 | EPHX1 (0.47) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| SCHEMBL31080572 | 0.86 | EPHX1 (0.47) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| SCHEMBL19506483 | 0.84 | HPGD (0.47) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| SCHEMBL17499855 | 0.84 | NR1H2 (0.43) | HPGDRECQLUSP2SMN1; SMN2CHRM2 | |
| SCHEMBL16714648 | 0.84 | NR1H2 (0.43) | HPGDRECQLUSP2SMN1; SMN2CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 223 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260109724-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES INC (US) | 2026-04-23 | — | — | US | disclosed |
| EP-4353715-B1 | 6-SUBSTITUTED CHIRALLY PURE DIFLUOROPIPERIDINE QUINAZOLINE DERIVATIVE AND PREPARATION METHOD THEREFOR | WEISHANG SHANGHAI BIO PHARMACEUTICAL CO LTD (CN) | 2026-04-15 | — | — | EP | disclosed |
| EP-4695238-A1 | CDK2 INHIBITORS | Blueprint Medicines Corporation (US) | 2026-02-18 | — | — | EP | disclosed |
| EP-4107164-B1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES INC (US) | 2025-12-03 | — | — | EP | disclosed |
| WO-2025215153-A1 | PRMT5 INHIBITORS | Ryvu Therapeutics S.A. (PL) | 2025-10-16 | — | — | WO | disclosed |
| US-20250289801-A1 | EGFR INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2025-09-18 | — | — | US | disclosed |
| US-20250276967-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES | SIGNAL PHARMACEUTICALS, LLC | 2025-09-04 | — | — | US | disclosed |
| US-20250276983-A1 | COMPOUNDS AND METHODS FOR MODULATING HER2 | IAMBIC THERAPEUTICS, INC. | 2025-09-04 | — | — | US | disclosed |
| EP-4577549-A1 | COMPOUNDS AND METHODS FOR MODULATING HER2 | Iambic Therapeutics, Inc. (US) | 2025-07-02 | — | — | EP | disclosed |
| US-12338235-B2 | Heterocyclic compounds and their use for treatment of helminthic infections and diseases | CELGENE CORPORATION (US) | 2025-06-24 | — | — | US | disclosed |
| US-9139524-B2 | Fluorinated bridged spiro[2.4]heptane derivatives as ALX receptor agonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2015-09-22 | — | — | US | disclosed |
| US-20150118258-A1 | Fluorinated Bridged Spiro[2.4]Heptane Derivatives as ALX Receptor Agonists | IDORSIA PHARMACEUTICALS LTD (CH) | 2015-04-30 | — | — | US | disclosed |
| US-8987251-B2 | Triazolopyridine compounds as PIM kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2015-03-24 | — | — | US | disclosed |
| US-20140045817-A1 | TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2014-02-13 | — | — | US | disclosed |
| US-8575145-B2 | Triazolopyridine compounds as PIM kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2013-11-05 | — | — | US | disclosed |
| EP-2334677-B1 | TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2013-10-09 | — | — | EP | disclosed |
| US-20130231319-A1 | Bridged Spiro[2.4]heptane Ester Derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-09-05 | — | — | US | disclosed |
| EP-2334677-A1 | TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2011-06-22 | — | — | EP | disclosed |
| US-20110144085-A1 | TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2011-06-16 | — | — | US | disclosed |
| WO-2010022076-A1 | TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2010-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260109724-A1 | ANTIVIRAL COMPOUNDS | IRF3, IFNAR1, HAVCR2 | HPGD 3520/4885RECQL 727/4885EPHX1 1627/4885 |
| US-20250276967-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES | CYP8B1, HAX1, HRH4 | HPGD 110/4885RECQL 253/4885EPHX1 51/4885 |
| US-12338235-B2 | Heterocyclic compounds and their use for treatment of helminthic infections and diseases | CYP8B1, HAX1, HRH4 | HPGD 110/4885RECQL 253/4885EPHX1 51/4885 |
| US-20110144085-A1 | TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS | PIM1, PIM2, PIM3 | HPGD 4505/4885RECQL 2306/4885EPHX1 3723/4885 |
| US-20140045817-A1 | TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS | PIM2, PIM1, PIM3 | HPGD 4307/4885RECQL 3294/4885EPHX1 4598/4885 |
| US-20250289801-A1 | EGFR INHIBITORS | EGFR, ERBB2, ERBB3 | HPGD 3657/4885RECQL 4012/4885EPHX1 3888/4885 |
| US-20130231319-A1 | Bridged Spiro[2.4]heptane Ester Derivatives | ADH1A, ADH1C, NAPA | HPGD 2709/4885RECQL 4762/4885EPHX1 4020/4885 |
| US-20250276983-A1 | COMPOUNDS AND METHODS FOR MODULATING HER2 | ERBB2, EGFR, ERBB3 | HPGD 2342/4885RECQL 3229/4885EPHX1 3667/4885 |
| US-20150118258-A1 | Fluorinated Bridged Spiro[2.4]Heptane Derivatives as ALX Receptor Agonists | FFAR1, ADGRF1, GPR52 | HPGD 1356/4885RECQL 2009/4885EPHX1 246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.